10-Q: Burzynski Research Institute Reports Q3 Losses Amid Clinical Hold

Burzynski Research Institute continues to report net losses and a significant accumulated deficit, remaining dependent on Dr. Burzynski's funding while its Antineoplaston clinical trials remain under full FDA clinical hold.

Summary

• Reported a net loss of $328,862 for the three months ended November 30, 2025, a decrease from $352,239 in the same period of 2024.
• For the nine months ended November 30, 2025, the net loss was $994,180, down from $1,093,409 in the prior year period.
• Research and development costs decreased by 13% to $260,800 for the three months and by 2% to $786,189 for the nine months ended November 30, 2025, primarily due to fewer regulatory requests.
• General and administrative expenses increased by 33% to $68,062 for the three months but decreased by 28% to $207,991 for the nine months ended November 30, 2025, influenced by regulatory filing requirements.
• The company's IND 43742 for Antineoplaston drugs remains under a full clinical hold by the FDA, preventing enrollment of new patients in any clinical trials.
• Burzynski Research Institute is entirely dependent on funding from Dr. S.R. Burzynski, M.D., Ph.D., through his medical practice for its capital and operational needs.
• As of November 30, 2025, the company had a working capital deficit of $67,343 and an accumulated deficit of $130,470,593.
• Cash and cash equivalents increased to $2,165 as of November 30, 2025, from $847 as of February 28, 2025.
• Dr. Burzynski contributed $968,474 in capital and paid $738,033 directly for FDA clinical trial expenses during the nine months ended November 30, 2025.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to persistent significant losses, a substantial accumulated deficit, a worsening working capital position, and the critical ongoing full FDA clinical hold on its primary drug candidate. The company's complete reliance on a single individual for funding and the explicit 'going concern' doubt further contribute to a very poor outlook, despite a slight reduction in net loss.

Positives

• Net loss decreased for both the three-month ($328,862 vs. $352,239) and nine-month ($994,180 vs. $1,093,409) periods ended November 30, 2025, compared to the prior year.
• Research and development costs decreased by 13% for the three months and 2% for the nine months ended November 30, 2025, primarily due to fewer regulatory requests.
• Net cash used in operating activities decreased to $967,156 for the nine months ended November 30, 2025, from $1,097,903 in the prior year, indicating a reduction in operational cash burn.
• Cash and cash equivalents increased to $2,165 as of November 30, 2025, from $847 as of February 28, 2025.

Negatives

• The company has not generated significant revenues since its inception and continues to incur recurring operating losses.
• A working capital deficit of $67,343 and an accumulated deficit of $130,470,593 as of November 30, 2025, indicate severe financial distress.
• The company's IND 43742 is under a full clinical hold by the FDA, preventing enrollment of new patients in any clinical trials for Antineoplaston drugs.
• There is substantial doubt about the company's ability to continue as a going concern due to its financial condition and dependency on a single individual for funding.
• General and administrative expenses increased by 33% for the three months ended November 30, 2025, due to increased professional fees and regulatory filing requirements.

Risks

• The company's ability to continue as a going concern is dependent upon the continued financial support of Dr. Burzynski through his medical practice, which is not assured.
• If Dr. Burzynski ceases funding, the company would be required to find immediate alternative funding, which may not be available on acceptable terms or at all, potentially leading to cessation of operations.
• There is no assurance that the company will ever achieve positive operating cash flow or be able to raise additional capital through equity or debt financing on acceptable terms.
• The full clinical hold on IND 43742 prevents the enrollment of new patients into any clinical trials, significantly delaying or preventing FDA approval of Antineoplaston drugs.
• Antineoplaston drugs have not received FDA approval, and there is no assurance that approval will be granted, which is critical for the company to exploit its licensed rights and generate revenue.
• Dr. Burzynski's medical practice, which funds the company, is subject to potential claims by patients and other claimants, and the risks associated with his practice directly affect his ability to fund the company's operations.
• The company is subject to numerous and complex FDA regulations and requirements, and there is a risk of non-compliance leading to sanctions.

Future Outlook

The company anticipates continued net losses and negative operating cash flows in the near future. Its ability to continue operations is entirely dependent on Dr. Burzynski's ongoing funding, with no assurance that he will be able to continue or that the company will achieve positive operating cash flow or FDA approval for its Antineoplaston drugs.

Management Comments

• "Management is evaluating strategic options to secure additional sources of capital through equity or debt financing, or other arrangements."
• "There can be no assurance that the Company will ever achieve positive operating cash flow."
• "Managements expectations and assumptions regarding Company operations and other future results are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements."

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, lengthy clinical trial processes, and significant regulatory hurdles, particularly FDA approval. Burzynski Research Institute operates within this challenging landscape, focusing on cancer treatment with Antineoplaston drugs. However, the company's prolonged clinical hold and complete reliance on a single individual for funding place it in a highly precarious position, far removed from typical industry development pathways that involve diverse funding sources and successful progression through clinical phases. The lack of significant revenue generation and the ongoing clinical hold highlight a severe deviation from the standard trajectory of a viable drug development company.

Comparison to Industry Standards

• Unlike most biotech companies that secure substantial venture capital or public market funding to advance drug candidates, Burzynski Research Institute remains entirely dependent on Dr. Burzynski's personal funding, which is highly unusual and unsustainable for long-term drug development.
• Successful oncology drug development typically involves clear progression through Phase I, II, and III trials, leading to FDA approval. Burzynski Research Institute's IND 43742 has been under a full clinical hold since 2017, a significant impediment that contrasts sharply with companies actively advancing candidates.
• Companies like Moderna (mRNA-1273 for COVID-19) or BioNTech (BNT162b2 for COVID-19) demonstrated rapid, successful clinical development and regulatory approval, showcasing efficient R&D and strong financial backing. Burzynski's situation, with decades of research and no FDA approval, indicates a profound lack of progress by industry standards.
• The accumulated deficit of over $130 million without any significant revenue generation is a stark contrast to successful biotech firms that either achieve profitability or are acquired after demonstrating clinical efficacy and market potential.
• The company's minimal cash balance of $2,165 and substantial working capital deficit are far below the liquidity levels typically required for ongoing R&D and operational expenses in the biotech sector, where cash reserves often span years of burn rate.

Corporate Governance

Related Party Transactions

• Dr. S.R. Burzynski, M.D., Ph.D., is the President, Chairman of the Board, and owner of approximately 81.0% of the outstanding common stock.
• The company is entirely dependent on Dr. Burzynski's medical practice for funding its capital and operational needs, including all basic research and clinical trial expenses.
• Dr. Burzynski contributed $968,474 in capital and paid $738,033 directly for FDA clinical trial expenses during the nine months ended November 30, 2025.
• The company operates under a New License Agreement with Dr. Burzynski, granting exclusive rights to Antineoplastons in the US and Canada, covering five US patents owned by him.
• A Research Funding Agreement with Dr. Burzynski dictates that he funds all scientific research and clinical trials, and provides laboratory and office space.
• A Royalty Agreement with Dr. Burzynski stipulates a 10% royalty on the company's gross income from Antineoplastons upon FDA approval.
• Under the Royalty Agreement, Dr. Burzynski has the right to produce Antineoplaston products for up to 1,000 patients without fees or purchase them at cost plus 10%.
• Dr. Burzynski owns the production facility at Trinity Drive, which the company uses without a formal lease agreement, as provided under the Research Funding Agreement.
• Dr. Burzynski's medical clinic performs certain administrative functions for the company, and he and the CFO are compensated through his medical practice, not directly by the company.

Stakeholder Impact

• Shareholders face significant risk due to the company's ongoing losses, accumulated deficit, complete financial dependency on Dr. Burzynski, and the indefinite clinical hold on its primary drug candidates, which casts substantial doubt on the company's ability to continue as a going concern.
• Employees (if any beyond Dr. Burzynski and CFO, whose salaries are paid by his medical practice) face job insecurity given the company's precarious financial state and reliance on external funding.
• Creditors face high risk due to the company's working capital deficit and lack of independent revenue streams, making repayment uncertain.
• Patients awaiting Antineoplaston treatments are directly impacted by the full clinical hold, as no new patients can be enrolled in trials, delaying potential access to the investigational drug.

Next Steps

• Resolve deficiencies regarding S.R. Burzynski's manufacturing facility to lift the full clinical hold on IND 43742.
• Seek additional capital through equity or debt financing or other arrangements to reduce dependency on Dr. Burzynski's funding.
• Continue efforts to obtain FDA approval for Antineoplaston drugs to enable commercial exploitation of licensed rights.
• The Research Funding Agreement is automatically renewable for an additional one-year term thereafter, unless one party notifies the other at least thirty days prior to expiration of its intention not to renew.

Key Dates

Recommendation

The company presents an extremely high-risk investment profile. It has no significant revenue, a massive accumulated deficit, and a worsening working capital position. Its entire operation is dependent on the personal funding of its majority shareholder, Dr. Burzynski, which is an unsustainable model for a public company. The core drug development program (Antineoplastons) is under a full FDA clinical hold, preventing any progress towards market approval, a situation that has persisted for years. There is explicit 'substantial doubt' about the company's ability to continue as a going concern. Given these fundamental and severe challenges, the stock is highly speculative with virtually no clear path to profitability or independent viability, making it a strong sell for any seasoned investor.

Keywords

Antineoplastons, cancer treatment, clinical trials, FDA clinical hold, biotechnology, pharmaceutical research, oncology, drug development, orphan drug designation, DIPG, glioblastoma, leptomeningeal disease